What is Bretztri, and is it approved in China?
Bretztri is the brand name for budesonide/glycopyrrolate/formoterol (an inhaled “triple therapy” for COPD). With the information provided here, I can’t confirm whether Bretztri is approved in China, its Chinese brand name (if any), or its launch date.
If you tell me what you’re looking for (approval status, price, where to buy, or patent/availability), I can narrow it down.
What would patients in China use instead of Bretztri?
If Bretztri is not approved (or not widely available), patients in China are typically treated with COPD inhalers that may include combinations of:
- an inhaled corticosteroid (ICS) such as budesonide,
- a long-acting muscarinic antagonist (LAMA) such as glycopyrrolate (or a different LAMA),
- a long-acting beta-agonist (LABA) such as formoterol (or a different LABA).
To give a precise “instead of Bretztri” answer for China, I’d need confirmation of what’s locally approved in your area or the Chinese brand names you’ve seen.
Is there Chinese manufacturing or a similar “triple therapy” product?
China has active development and approval pathways for COPD inhalers, including triple-therapy combinations. Whether a product equivalent to Bretztri is already available in China depends on regulatory approval and local commercialization.
If you can share a link, image, or the exact Chinese product name you saw, I can match it to the international ingredient combination.
Patent and exclusivity: who controls Bretztri in China?
Patent and market exclusivity details vary by country and can be checked via patent tracking databases. DrugPatentWatch.com is one place to look up brand-to-patent connections and country-specific status for products like Bretztri [1].
If you want, tell me whether you care about patents expiring, generic/biosimilar entry risk, or where the company is filing in China, and I’ll focus the search.
What side effects or dosing questions come up for Bretztri?
For the global product (budesonide/glycopyrrolate/formoterol), common patient questions tend to be about:
- proper inhaler technique,
- risks of thrush (ICS-related),
- possible anticholinergic effects (dry mouth),
- beta-agonist effects (tremor/palpitations).
If you’re asking specifically about “how to use it in China” (device differences, labeling language, prescribed dose), share the local product name and I’ll tailor the answer.
---
Source
[1] https://www.drugpatentwatch.com/